"This patent represents yet another milestone in Entelos' intellectual property strategy, and indicates the company's commitment to protecting its leadership position in the field of predictive biosimulation", stated Charles Sholtz, J.D., Ph.D., Vice President, Legal Affairs and Intellectual Property at Entelos. "Currently, we have 12 issued patents and over 70 pending applications worldwide directed to our software platform; the methodologies of applying our PhysioLab models to pharmaceutical drug discovery and development; and the PhysioLab models themselves."
This patent provides broad coverage for a method to consecutively link biosimulation experiments using a computer model. The software based on this method allows Entelos scientists to rapidly create new virtual patients and effectively use them to validate drug targets, identify biomarkers, translate preclinical data to human outcome, and optimize clinical trial designs.
"By developing this methodology, Entelos can effectively represent patient variability in a computer on both the individual and population scale", stated James Karis, President and CEO of Entelos. "This ability allows us to address this critical drug development challenge, which is also a key hurdle in fulfilling the promise of personalized medicine. This patent further strengthens our leadership position in biosimulation and lays the framework for Entelos to develop the first-ever virtual human."
Entelos Inc. is a biotechnology company focused on discovering and developing new therapies for metabolic and inflammatory disorders. Its mission is to leverage a unique predictive capability in human biology to dramatically improve how medicines are discovered, developed, and brought to market. Using its proprietary PhysioLab biosimulation platforms - computer-based mathematical models of human disease, Entelos systematically uncovers the biological mechanisms underlying a disease in order to identify potential points of therapeutic intervention and the patients most likely to benefit. In addition to its internal research programmes, Entelos partners with pharmaceutical and biotechnology organisations worldwide. More news is available in the VMW July 2004 article Roche Diagnostics and Entelos receive Best Practices Award from Bio-IT World for predictive biosimulation.